Abpro Chairman & CEO Ian Chan and Shahraab Ahmad, Chairman & CEO of Atlantic Coastal II

Developing new medical treatments takes time and money, which is
generally where investors come in. But, Abpro has
managed to resolve many of those questions before SPAC investors
will join the show.


This week, we speak with Abpro Chairman and CEO Ian
Chan and Shahraab Ahmad, Chairman and CEO of Atlantic
Coastal Acquisition Corp II (Nasdaq: ACAB). The two
announced a $500 million combination in January.


Shahraab explains how Abpro came onto Atlantic Coastal II’s radar
after the SPAC had originally been fishing in the mobility
space, and why the particularities of its capital needs
could be a fit for the current market conditions.


Ian also walks through Abpro’s clinical path moving forward and
how it can use a mix of its internal discovery engines and
M&A to expand its portfolio.


Ian also walks through Abpro’s clinical path moving forward and
how it can use a mix of its internal discovery engines and
M&A to expand its portfolio.